An Aptamer‐Based EXACT Anticoagulant as a Sustainable, Animal‐Free Alternative to Unfractionated Heparin
Advanced Science · 2026
DOI: 10.1002/advs.202509867 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Haixiang Yu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Duke University, Durham, NC, 27710, USA. Hauptthemen laut MEDLINE: Anticoagulants, Heparin, Aptamers, Nucleotide. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NIGMS NIH HHS, American Heart Association.
Abstract (Originalsprache)
Unfractionated heparin (UFH), designated as an essential medicine by the World Health Organization (WHO), is indispensable in cardiac surgery and various clinical applications. However, its production depends on the farming of over a billion large animals annually, posing sustainability challenges, especially amidst increasing efforts to mitigate greenhouse gas (GHG) emissions by reducing animal farming. The rising demand for UFH has outpaced its supply, and previous attempts to develop synthetic alternatives have fallen short because of their limited potency and reversibility. Here, HD1‐12dmA‐DAB is presented, a novel synthetic anticoagulant developed through chemical conjugation of a thrombin exosite‐binding aptamer (HD1) with a thrombin active‐site inhibitor (dabigatran). By optimizing dual‐site synergistic binding, HD1‐12dmA‐DAB achieves an enhancement of over three orders of magnitude in thrombin‐binding affinity and specificity compared to HD1 alone. It also demonstrates superior plasma stability and anticoagulant efficacy comparable to UFH, as validated in in vitro, in vivo, and ex vivo clotting models. This breakthrough highlights a promising step toward a sustainable, animal‐free alternative to UFH, addressing the growing clinical demand and advancing environmental sustainability objectives.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Duke University, Durham, NC, 27710, USA.
- Department of Biochemistry, School of Life Science and Technology, China Pharmaceutical University, Nanjing, 211198, China.
- Department of Medicine, Duke University, Durham, NC, 27710, USA.
- Department of Emergency Medicine, Duke University Hospital, Durham, NC, 27710, USA.
- School of Medicine, Duke University, Durham, NC, 27710, USA.
- Departments of Pharmacology & Cancer Biology, Cell Biology and Biomedical Engineering, Duke University, Durham, NC, 27710, USA.
ORCID-Profile: Bruce A Sullenger
Förderung
- NHLBI NIH HHS
- NIGMS NIH HHS
- American Heart Association
- National Heart, Lung, and Blood Institute
Zitieren
APA
Yu, H., Pitoc, G., Zhang, M., Clancy, J., Frederiksen, J., Yan, A., Francis, S., Sullenger, R., Rempel, R., Gammell, S., Caiazzi, J., & Sullenger, B. A. (2026). An Aptamer‐Based EXACT Anticoagulant as a Sustainable, Animal‐Free Alternative to Unfractionated Heparin. Advanced Science. https://doi.org/10.1002/advs.202509867
Vancouver
Yu H, Pitoc G, Zhang M, Clancy J, Frederiksen J, Yan A, et al. An Aptamer‐Based EXACT Anticoagulant as a Sustainable, Animal‐Free Alternative to Unfractionated Heparin. Advanced Science. 2026. doi:10.1002/advs.202509867
BibTeX
@article{Yu2026,
author = {Yu, Haixiang and Pitoc, George and Zhang, Manqi and Clancy, Jeffrey and Frederiksen, James and Yan, Amy and Francis, Samuel and Sullenger, Rebecca and Rempel, Rachel and Gammell, Susannah and Caiazzi, Jillian and Sullenger, Bruce A},
title = {An Aptamer‐Based EXACT Anticoagulant as a Sustainable, Animal‐Free Alternative to Unfractionated Heparin},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.202509867}
}
EUVIMED